A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
Clinical trial NCT02945215 · COMPLETED
Trial details
- NCT number
- NCT02945215
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-13
- Primary completion
- 2019-03-21
- Enrollment
- 181
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.